<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35485374</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1699-5198</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>Nutricion hospitalaria</Title><ISOAbbreviation>Nutr Hosp</ISOAbbreviation></Journal><ArticleTitle>[Handling of drugs for administration by percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and enteral nutrition].</ArticleTitle><Pagination><StartPage>716</StartPage><EndPage>722</EndPage><MedlinePgn>716-722</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.20960/nh.03946</ELocationID><Abstract><AbstractText>Introduction: amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Its symptoms include dysphagia that may make it necessary to place a percutaneous endoscopic gastrostomy (PEG) for feeding. The administration of drugs by PEG can obstruct it, decrease the effectiveness of treatment, and increase the risk of toxicity by altering the original pharmaceutical form. Objective: to describe and analyze the degree of adequacy of the prescription of drugs administered by PEG in patients with ALS and with enteral nutrition (EN). Material and methods: the prescription of pharmacological treatment for patients with ALS who were admitted for placement of a PEG was reviewed. The degree of adequacy of the prescribed drugs was analyzed according to criteria of loss of efficacy, toxicity, risk for handler, and compatibility with EN by consulting the available scientific evidence. Results: the medical prescriptions of the treatments of 34 patients were reviewed, with a total of 307 medications (median of 9 drugs per patient, range 2-17). Via PEG 267 oral medications (median 8 per patient, range 2-15) were prescribed; 81.65 % were solid forms, and the pharmaceutical form was modified in 43 %, due to the risk of catheter occlusion, toxicity or loss of efficacy, affecting 97 % of the patients. Conclusions: patients with ALS and PEG are at risk of presenting safety problems and loss of treatment efficacy related to alteration of the original pharmaceutical form and the interaction with EN.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>V&#xe1;zquez Polo</LastName><ForeName>Amparo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Servicio de Farmacia. Hospital Universitari i Polit&#xe8;cnic La Fe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez Briz</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Farmacia. Hospital Universitari i Polit&#xe8;cnic La Fe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poveda Andr&#xe9;s</LastName><ForeName>Jos&#xe9; Lu&#xed;s</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Servicio de Farmacia. Hospital Universitari i Polit&#xe8;cnic La Fe.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xe1;zquez Costa</LastName><ForeName>Juan Francisco</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Servicio de Neurolog&#xed;a. Hospital Universitari i Polit&#xe8;cnic La Fe.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Manipulaci&#xf3;n de f&#xe1;rmacos para su administraci&#xf3;n por gastrostom&#xed;a endosc&#xf3;pica percut&#xe1;nea en pacientes con esclerosis lateral amiotr&#xf3;fica y nutrici&#xf3;n enteral.</VernacularTitle></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Nutr Hosp</MedlineTA><NlmUniqueID>9100365</NlmUniqueID><ISSNLinking>0212-1611</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004750" MajorTopicYN="N">Enteral Nutrition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005774" MajorTopicYN="N">Gastrostomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Introducci&#xf3;n: la esclerosis lateral amiotr&#xf3;fica (ELA) es una enfermedad neurodegenerativa. Entre sus s&#xed;ntomas destaca la disfagia, que hace necesaria la colocaci&#xf3;n de una gastrostom&#xed;a endosc&#xf3;pica percut&#xe1;nea (PEG) para alimentarse. La administraci&#xf3;n de f&#xe1;rmacos por la PEG puede obstruirla, disminuir la eficacia del tratamiento y aumentar el riesgo de toxicidad, al alterar la forma farmac&#xe9;utica original. Objetivo: describir y analizar el grado de adecuaci&#xf3;n de la prescripci&#xf3;n de f&#xe1;rmacos administrados por PEG en pacientes con ELA y con nutrici&#xf3;n enteral (NE). Material y m&#xe9;todos: se revis&#xf3; la prescripci&#xf3;n del tratamiento farmacol&#xf3;gico de los pacientes con ELA que ingresaban para la colocaci&#xf3;n de una PEG. Se analiz&#xf3; el grado de adecuaci&#xf3;n de los f&#xe1;rmacos prescritos seg&#xfa;n los criterios de p&#xe9;rdida de eficacia, toxicidad, riesgo para el manipulador y compatibilidad con la NE, consultando la evidencia cient&#xed;fica disponible. Resultados: se revisaron las prescripciones m&#xe9;dicas de los tratamientos de 34 pacientes, con un total de 307 medicamentos (mediana de 9 f&#xe1;rmacos por paciente; rango, 2-17). Se pautaron por la PEG 267 medicamentos de administraci&#xf3;n oral (mediana de 8 por paciente; rango, 2-15). El 81,65 % fueron formas s&#xf3;lidas y se modific&#xf3; la forma farmac&#xe9;utica en el 43 % por riesgo de oclusi&#xf3;n de la sonda, toxicidad o p&#xe9;rdida de eficacia, afectando al 97 % de los pacientes. Conclusiones: los pacientes con ELA y con PEG tienen riesgo de presentar problemas de seguridad y de p&#xe9;rdida de eficacia del tratamiento relacionados con la alteraci&#xf3;n de la forma farmac&#xe9;utica original y de la interacci&#xf3;n con la NE.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Esclerosis lateral amiotr&#xf3;fica. Gastrostom&#xed;a endosc&#xf3;pica percut&#xe1;nea. Interacci&#xf3;n f&#xe1;rmaco-nutriente. Medicamentos peligrosos. Nutrici&#xf3;n enteral. Sondas digestivas.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35485374</ArticleId><ArticleId IdType="doi">10.20960/nh.03946</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">29776887</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2173-5743</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2 Pt 1</Issue><PubDate><Year>2020</Year><Season>Mar-Apr</Season></PubDate></JournalIssue><Title>Reumatologia clinica</Title><ISOAbbreviation>Reumatol Clin (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study.</ArticleTitle><Pagination><StartPage>116</StartPage><EndPage>119</EndPage><MedlinePgn>116-119</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.reuma.2018.02.015</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1699-258X(18)30076-7</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">In the ARCO study, adherence to subcutaneous biological agents by patients with rheumatoid arthritis improved with monthly administration. We assess whether adherence can be related to fulfillment of expectations and satisfaction with treatment.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Adherence was assessed by calculating the Medication Possession Ratio, and satisfaction and fulfillment of expectations using the &#xab;EXPRESAR&#xbb; group questionnaire.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In 346 patients, those who were satisfied/very satisfied with efficacy and tolerability were &#x2265;80% and 64.4%, with no differences between weekly, biweekly or monthly administration regimens. Regarding the fulfillment of expectations, 59.9% considered the effect of the treatment greater than expected and 52.6% reported lower/much lower than expected discomfort; the latter percentage was higher in patients with monthly administration (P=.049). The percentages for nonadherence were 15.6% (discomfort greater than expected), 18.5% (expected discomfort) and 11.1% (lower than expected or no discomfort) (P=.189).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Satisfaction and fulfillment of expectations were high. Fulfillment of expectations of tolerability was better with monthly administration, which could contribute to better adherence.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Sociedad Espa&#xf1;ola de Reumatolog&#xed;a y Colegio Mexicano de Reumatolog&#xed;a. Publicado por Elsevier Espa&#xf1;a, S.L.U. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calvo-Al&#xe9;n</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Servicio de Reumatolog&#xed;a, Hospital Txagorritxu, Vitoria-Gasteiz, &#xc1;lava, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vela</LastName><ForeName>Paloma</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Servicio de Reumatolog&#xed;a, Hospital Universitario de Alicante, Alicante, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustabad</LastName><ForeName>Sagrario</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Servicio de Reumatolog&#xed;a, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Tenerife, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maceiras</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Servicio de Reumatolog&#xed;a, Complejo Hospitalario Universitario de Vigo, Vigo, La Coru&#xf1;a, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmona</LastName><ForeName>Loreto</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Instituto de Salud Musculoesquel&#xe9;tica, Madrid, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cea-Calvo</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Affairs, Merck Sharp &amp; Dohme de Espa&#xf1;a, Espa&#xf1;a. Electronic address: luis.cea@merck.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><VernacularTitle>Satisfacci&#xf3;n, cumplimento de expectativas y adherencia al f&#xe1;rmaco biol&#xf3;gico subcut&#xe1;neo en pacientes con artritis reumatoide. Estudio ARCO.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Reumatol Clin (Engl Ed)</MedlineTA><NlmUniqueID>101717526</NlmUniqueID><ISSNLinking>2173-5743</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="Y">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000099059" MajorTopicYN="Y">Assessment of Medication Adherence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adherence</Keyword><Keyword MajorTopicYN="N">Adherencia</Keyword><Keyword MajorTopicYN="N">Artritis reumatoide</Keyword><Keyword MajorTopicYN="N">Biological drugs</Keyword><Keyword MajorTopicYN="N">Expectations</Keyword><Keyword MajorTopicYN="N">Expectativas</Keyword><Keyword MajorTopicYN="N">F&#xe1;rmacos biol&#xf3;gicos</Keyword><Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29776887</ArticleId><ArticleId IdType="doi">10.1016/j.reuma.2018.02.015</ArticleId><ArticleId IdType="pii">S1699-258X(18)30076-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27269219</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1699-5198</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>Suppl 1</Issue><PubDate><Year>2016</Year><Month>Jun</Month><Day>03</Day></PubDate></JournalIssue><Title>Nutricion hospitalaria</Title><ISOAbbreviation>Nutr Hosp</ISOAbbreviation></Journal><ArticleTitle>[Not Available].</ArticleTitle><Pagination><StartPage>179</StartPage><MedlinePgn>179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.20960/nh.179</ELocationID><Abstract><AbstractText>Durante la &#xfa;ltima d&#xe9;cada, el conocimiento de nuevos mecanismos implicados en el desarrollo del c&#xe1;ncer ha permitido el dise&#xf1;o de nuevos f&#xe1;rmacos para su tratamiento y la mayor parte de ellos son f&#xe1;rmacos que se administran por v&#xed;a oral. Uno de los principales problemas de los pacientes oncohematol&#xf3;gicos es la desnutrici&#xf3;n, que suele tener causas multifactoriales (de la propia enfermedad, de los pacientes y de los diferentes tratamientos administrados). Para minimizar el impacto de la desnutrici&#xf3;n es necesaria una intervenci&#xf3;n nutricional, ya sea adaptando la dieta o mediante la instauraci&#xf3;n de soporte nutricional artificial, en funci&#xf3;n de la gravedad de cada caso. En cualquier paciente que est&#xe9; recibiendo un tratamiento oncol&#xf3;gico hay que evaluar las posibles interacciones que pueden existir con el soporte nutricional instaurado, ya sea dieta oral, suplementaci&#xf3;n oral o nutrici&#xf3;n enteral. Estas interacciones pueden disminuir la eficacia, aumentar la toxicidad de los tratamientos o producir d&#xe9;ficits nutricionales. Se detallan las principales interacciones que se pueden producir, las interacciones entre los tratamientos oncol&#xf3;gicos y el soporte nutricional.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fort Casamartina</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>. efort@iconcologia.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arribas Hortiguela</LastName><ForeName>Lorena</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Bleda P&#xe9;rez</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz S&#xe1;nchez</LastName><ForeName>Carme</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Peiro Mart&#xed;nez</LastName><ForeName>Imma</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Perayre Bad&#xed;a</LastName><ForeName>Mar&#xed;a</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Clop&#xe9;s Estela</LastName><ForeName>Ana</ForeName><Initials>A</Initials></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Interacci&#xf3;n entre tratamientos oncol&#xf3;gicos y soporte nutricional.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Nutr Hosp</MedlineTA><NlmUniqueID>9100365</NlmUniqueID><ISSNLinking>0212-1611</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044342" MajorTopicYN="N">Malnutrition</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018529" MajorTopicYN="N">Nutritional Support</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">F&#xe1;rmaco</Keyword><Keyword MajorTopicYN="N">Interacci&#xf3;n</Keyword><Keyword MajorTopicYN="N">Nutrici&#xf3;n enteral</Keyword><Keyword MajorTopicYN="N">Nutriente</Keyword><Keyword MajorTopicYN="N">Quimioterapia oral</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27269219</ArticleId><ArticleId IdType="doi">10.20960/nh.179</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24485970</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-8865</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>5</Issue><PubDate><Year>2014</Year><Season>Jul-Aug</Season></PubDate></JournalIssue><Title>Semergen</Title><ISOAbbreviation>Semergen</ISOAbbreviation></Journal><ArticleTitle>[Relationship between antihypertensive drug use and development of atrial fibrillation in hypertensive patients in a Primary Care center].</ArticleTitle><Pagination><StartPage>247</StartPage><EndPage>253</EndPage><MedlinePgn>247-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.semerg.2013.10.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1138-3593(13)00284-0</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Although antihypertensive treatment can reduce the risk of cardiovascular morbimortality, studies aimed at evaluating the association between antihypertensive drug use and incidence of atrial fibrillation (AF) yield mixed results. This study aimed to determine the possible relationship between antihypertensive drug use and development of AF.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Case control study.</AbstractText><AbstractText Label="CASES" NlmCategory="METHODS">Hypertensive patients with AF diagnosed at least one year after the start of drug treatment for hypertension.</AbstractText><AbstractText Label="CONTROLS" NlmCategory="METHODS">Hypertensive patients without AF with pharmacological antihypertensive treatment for at least one year, matching by sex, age and duration of antihypertensive therapy at diagnosis of AF cases. The study included 136 cases and 132 controls.</AbstractText><AbstractText Label="VARIABLES" NlmCategory="METHODS">AF, antihypertensive drugs, control of hypertension, duration of treatment with antihypertensive drugs, number of antihypertensive drugs.</AbstractText><AbstractText Label="ANALYSIS" NlmCategory="METHODS">Crude OR were calculated, with logistic regression being used to calculate the adjusted odds ratios.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, diuretics was close to statistical significance: OR 0.616 (95% CI 0.365 to 1.040), as a protective factor for development of AF. Calcium channel blockers behaved as a protective factor against development of AF at 75 years or older (OR 0.366; 95% CI 0.173 to 0.772), and within this age in women (OR 0.343; 95% CI 0.145-0.811).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Calcium channel blockers in the group of 75 years or more, especially in women, worked statistically significant as a drug protecting against the appearance of AF. Diuretics may have a protective role in AF incidence in all hypertensive patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2013 Sociedad Espa&#xf1;ola de M&#xe9;dicos de Atenci&#xf3;n Primaria (SEMERGEN). Publicado por Elsevier Espa&#xf1;a. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mena-Villalba</LastName><ForeName>A &#xc1;</ForeName><Initials>A&#xc1;</Initials><AffiliationInfo><Affiliation>Unidad de Gesti&#xf3;n Cl&#xed;nica, Centro de Salud Puerto Real, Distrito de Atenci&#xf3;n Primaria C&#xe1;diz, Bah&#xed;a, La Janda, Servicio Andaluz de Salud, Puerto Real, C&#xe1;diz, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lend&#xed;nez-de la Cruz</LastName><ForeName>J M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Unidad de Gesti&#xf3;n Cl&#xed;nica, Centro de Salud Puerto Real, Distrito de Atenci&#xf3;n Primaria C&#xe1;diz, Bah&#xed;a, La Janda, Servicio Andaluz de Salud, Puerto Real, C&#xe1;diz, Espa&#xf1;a. Electronic address: jlendinezd@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cubero-G&#xf3;mez</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Unidad de Gesti&#xf3;n Cl&#xed;nica, Centro de Salud Puerto Real, Distrito de Atenci&#xf3;n Primaria C&#xe1;diz, Bah&#xed;a, La Janda, Servicio Andaluz de Salud, Puerto Real, C&#xe1;diz, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monsalvo-Moro</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Gesti&#xf3;n Cl&#xed;nica, Centro de Salud Puerto Real, Distrito de Atenci&#xf3;n Primaria C&#xe1;diz, Bah&#xed;a, La Janda, Servicio Andaluz de Salud, Puerto Real, C&#xe1;diz, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guti&#xe9;rrez-Ru&#xed;z</LastName><ForeName>R C</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Unidad de Gesti&#xf3;n Cl&#xed;nica, Centro de Salud Puerto Real, Distrito de Atenci&#xf3;n Primaria C&#xe1;diz, Bah&#xed;a, La Janda, Servicio Andaluz de Salud, Puerto Real, C&#xe1;diz, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xed;a-Alfons&#xed;n</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unidad de Gesti&#xf3;n Cl&#xed;nica, Centro de Salud Puerto Real, Distrito de Atenci&#xf3;n Primaria C&#xe1;diz, Bah&#xed;a, La Janda, Servicio Andaluz de Salud, Puerto Real, C&#xe1;diz, Espa&#xf1;a.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Relaci&#xf3;n entre el f&#xe1;rmaco antihipertensivo utilizado y la aparici&#xf3;n de fibrilaci&#xf3;n auricular en los pacientes hipertensos de un centro de Atenci&#xf3;n Primaria.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Semergen</MedlineTA><NlmUniqueID>9610769</NlmUniqueID><ISSNLinking>1138-3593</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002121">Calcium Channel Blockers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004232">Diuretics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="N">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002121" MajorTopicYN="N">Calcium Channel Blockers</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004232" MajorTopicYN="N">Diuretics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antihypertensive drug</Keyword><Keyword MajorTopicYN="N">Atrial fibrillation</Keyword><Keyword MajorTopicYN="N">Fibrilaci&#xf3;n auricular</Keyword><Keyword MajorTopicYN="N">F&#xe1;rmacos antihipertensivos</Keyword><Keyword MajorTopicYN="N">High blood pressure</Keyword><Keyword MajorTopicYN="N">Hipertensi&#xf3;n arterial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24485970</ArticleId><ArticleId IdType="doi">10.1016/j.semerg.2013.10.006</ArticleId><ArticleId IdType="pii">S1138-3593(13)00284-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>